BRIEF published on 06/03/2026 at 18:15, 1 month 27 days ago RedHill Biopharma Explores Opaganib for Ebola Virus Amid Outbreak Clinical Trials Infectious Disease Ebola Virus Opaganib RedHill Biopharma
PRESS RELEASE published on 06/03/2026 at 18:10, 1 month 27 days ago RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak RedHill Biopharma is exploring collaboration opportunities to advance opaganib for Ebola virus disease outbreak, with potential host-directed therapeutic benefits and dual mechanism of action Collaboration Clinical Advancement Opaganib RedHill Biopharma Ebola Virus Disease
Published on 07/31/2026 at 01:39, 4 hours 49 minutes ago Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 6 hours 43 minutes ago Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 7 hours 27 minutes ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 7 hours 28 minutes ago Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:45, 11 hours 43 minutes ago First Canadian Graphite Reports High-Grade Graphite Prospecting Results up to 43.4% Cg at Lac Guéret South Project
Published on 07/31/2026 at 00:00, 6 hours 27 minutes ago EQS-Adhoc: VIB Vermögen AG: Agreements on the restructuring of financial liabilities of BRANICKS Group AG signed, incl. commitment for a € 60 mn financing for VIB Vermögen AG
Published on 07/30/2026 at 23:48, 6 hours 39 minutes ago BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 23:46, 6 hours 41 minutes ago EQS-Adhoc: Branicks Group AG: BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 22:05, 8 hours 22 minutes ago Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Published on 07/30/2026 at 20:45, 9 hours 42 minutes ago Delay is Unacceptable | Petrus Recommends Shareholders Not to Tender at €14.10 per Share
Published on 07/30/2026 at 18:15, 12 hours 12 minutes ago Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:00, 12 hours 28 minutes ago PR ICADE – ACQUISITION OF A CONTROLLING INTEREST IN COMET
Published on 07/30/2026 at 18:00, 12 hours 28 minutes ago GUILLEMOT CORPORATION: 2026 first-half turnover / Strong consumer demand and a second half with a strong lineup of major product launches
Published on 07/30/2026 at 17:50, 12 hours 37 minutes ago NRJ GROUP - Press release Half-Year Results 2026
